Research & Development
Prostate Cancer: Page 4
MiR Scientific, Leonie Hill to partner on prostate cancer test
The test uses a single urine sample to identify prostate cancer and classify disease severity, according to miR Scientific. Its technology is based on analyzing small noncoding RNAs taken from urinary exosomes; clinical studies have shown that it can find and categorize clinically significant prostate cancer with more than 90% accuracy, the company said.
March 27, 2022
Lunaphore, MGH collaborate on IVD work for solid tumors
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
Datar secures FDA breakthrough nod for prostate cancer test
TriNetra-Prostate identifies early-stage prostate cancer in men between the ages of 55 and 69 with more than 99% accuracy, the company said. It requires 5 ml of blood and is indicated for men with a serum prostate-specific antigen (PSA) measure of 3 ng/mL or higher, according to Datar.
February 13, 2022
Veracyte to highlight new Decipher data at ASCO meeting
The abstracts report results from a phase III study that evaluated the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from diagnostic biopsy specimens, Veracyte said.
January 30, 2022
Paige AI software gets U.K. medtech innovation evaluation
MIBs are intended to support the U.K.'s National Health Service (NHS) facilities when they are considering the use of new medical devices, Paige said. This MIB is the first for a digital pathology product, according to the firm.
December 5, 2021
Deep Bio, Tribun collaborate on AI-based digital pathology
DeepDx, Deep Bio's deep learning-based prostate cancer diagnostic support software, will be integrated with CaloPix, part of the Tribun Health Platform. Using CaloPix, pathologists can now leverage automated prostate cancer image analysis using AI, Deep Bio said.
November 30, 2021
AI of pathology slides improves prostate cancer diagnosis
The study suggests that AI has the potential to transform histopathological evaluation and optimize the risk stratification and clinical management of prostate cancer, giving it more of a precision approach, according to the study's authors, from the University of Wisconsin and elsewhere.
November 3, 2021
Immunis.AI touts results from prostate liquid biopsy study
Immunis.AI's Intelligentia platform also can stratify the risk in men considering active surveillance of prostate cancer, according to the results published in Cells. (Cells, September 28, 2021, Vol. 10, pp. 2567.)
October 12, 2021
Caris, Essa introduce program for prostate cancer inhibitor
EPI-7386 is an N-terminal domain androgen receptor inhibitor intended for patients with metastatic castration-resistant prostate cancer failing current standard-of-care therapies.
October 7, 2021
Immunis.AI closes on funding for immunogenomic platform
The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.
September 30, 2021
Saliva test based on microRNA detects prostate cancer
The test distinguishes prostate cancer from benign prostatic hyperplasia (BPH), a benign enlargement of the prostate that can occur as men age. The test can detect eight different microRNAs that either support or suppress tumor growth, according to the researchers, who were led by Drs. Jamal Amri and Mona Alaee of the Tehran University of Medical Sciences.
September 28, 2021
FDA clears 1st prostate pathology AI software application
Designed to serve as an adjunct to pathologist review of digitized prostate biopsy images, Paige Prostate identifies areas of interest on the images that contain the highest likelihood of cancer. Pathologists can then further review the AI findings if they had not identified these areas of concern on their initial evaluation, according to the FDA.
September 20, 2021
Page 4 of 7